All Pooled News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from All Pooled. Real-time updates on events, politics, business and more.

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

January 17, 2024

HAYWARD, Calif.--(BUSINESS WIRE)--Jan 16, 2024--

University Of California Los Angeles United States Holli Kolkey Zeva Wainberg Exchange Commission Arcus Biosciences Inc

Source: eagletribune.com

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

January 16, 2024

Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A...

United States Zeva Wainberg Gilead Sciences Arcus Biosciences Inc Exchange Commission Arcus Biosciences

Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

All Pooled News Today

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Na&#xEF;ve Metastatic Pancreatic Cancer

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Na&#xEF;ve Metastatic Pancreatic Cancer

Explore More Categories

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer